DARPin delay drops Allergan despite earnings rise
This article was originally published in Scrip
Allergan reported an 18% earnings increase and an 8.4% rise in net product sales for the first quarter of 2013, but its stock fell 13.1% to $98.67 per share on 1 May after the company revealed delays for two key pipeline programs, including its Phase II anti-VEGF candidate for the treatment of wet age-related macular degeneration (AMD).
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.